Overview

Sublingual vs IV Atropine Bioavailability Study

Status:
Completed

Trial end date:
2020-02-08

Target enrollment:

Participant gender:

Summary

This randomized, three-sequence, three-period, phase 1 study is designed to assess the bioavailability and pharmacokinetics (PK) of sublingually administered atropine sulfate ophthalmic solution 1% USP (at 0.5 mg and 1.0 mg; test) compared to atropine sulfate injection administered IV (1.0 mg; reference).

Phase:

Phase 1

Details

Lead Sponsor:

Biomedical Advanced Research and Development Authority

Collaborator:

Rho, Inc.

Treatments:

Atropine
Benzalkonium Compounds
Muscarinic Antagonists
Ophthalmic Solutions
Pharmaceutical Solutions